Incyte (INCY) Receivables (2010 - 2026)
Incyte's (INCY) quarterly Receivables came in at $1.1 billion in Q2 2026, up 33.49% YoY from $842.9 million in Q2 2025, and up 7.01% on a QoQ basis from $1.1 billion in Q1 2026.
Incyte (INCY) Receivables (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Receivables data on file, last reported at $1.1 billion in Q2 2026.
- Quarterly Receivables rose 33.49% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 33.49% YoY) and the FY2025 annual result came in at $1.0 billion, up 20.07% from the prior year.
- Receivables advanced to $1.1 billion in Q2 2026, from $1.1 billion in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.1 billion in Q2 2026 to a low of $562.3 million in Q1 2022.
- A 5-year average of $779.5 million and a median of $744.5 million in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables soared 55.87% — and 2023, when it slipped 6.59%.
- Tracing INCY's Receivables over 5 years: stood at $644.9 million in 2022, then climbed by 15.3% to $743.6 million in 2023, then rose by 14.74% to $853.2 million in 2024, then grew by 20.07% to $1.0 billion in 2025, then advanced by 9.84% to $1.1 billion in 2026.
- The last three Receivables figures came in at $1.1 billion (Q2 2026), $1.1 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn | 1.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Bn |
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 1.02 Bn |
| Sep 30, 2025 | 895.89 Mn |
| Jun 30, 2025 | 842.89 Mn |
| Mar 31, 2025 | 823.13 Mn |
| Dec 31, 2024 | 853.15 Mn |
| Sep 30, 2024 | 758.45 Mn |
| Jun 30, 2024 | 739.05 Mn |
| Mar 31, 2024 | 745.53 Mn |
| Dec 31, 2023 | 743.56 Mn |
| Sep 30, 2023 | 657.26 Mn |
| Jun 30, 2023 | 637.99 Mn |
| Mar 31, 2023 | 623.79 Mn |
| Dec 31, 2022 | 644.88 Mn |
| Sep 30, 2022 | 618.19 Mn |
| Jun 30, 2022 | 682.97 Mn |
| Mar 31, 2022 | 562.34 Mn |
| Dec 31, 2021 | 616.30 Mn |
| Sep 30, 2021 | 516.69 Mn |